A New Targeted Therapy Pill Extends Lives of Patients with Metastatic Renal Cell Carcinoma, RCC


In the phase III trial, more than 300 patients with metastatic RCC were randomly chosen to receive Fotivda (Tivozanib) or Nexavar (Sorafenib) for a median of 19 months. While Nexavar is already approved by the Food and Drug Administration (FDA), Fotivda, an oral VEGFR inhibitor that stops the growth of new blood vessels that fuel tumors, is not.

The patients were recruited from more than 120 centers in 12 different countries in the US and Europe. Treatment began in May 2016.


  • At one year, 28% of patients with Fotivda did not suffer worsening of their disease compared with 11% treated with Nexavar.
  • At two years, 18% with Fotivda did not suffer worsening of their disease compared with 5% in the Nexavar group.
  • At the study’s end, 70 patients (40%) in the Fotivda group and 82 patients (47%)  in the Nexavar group saw their disease progress.

Adverse Events

The most common treatment-related side effects were hypertension (20% of patients treated with Fotivda and 14% of patients treated with Nexavar).

Serious treatment-related side effects were seen in 11% of patients in the Fotivda group and 10% in the Nexavar group.


This agent has shown in clinical trials to be effective in delaying cancer growth beyond established standard protocols for patients who have returning kidney cancer. Although there are many options for patients with kidney cancer today, most are intended for first- and second-line therapy. We need a treatment like Fotivda that works for kidney cancer patients who have failed several lines of therapy.

The best treatment for a cancer patient is to get the most advanced cancer drugs in advanced stages of development. There, the hope and the chance to extend life go far beyond the standard protocols.

Contact us to find out what is the best treatment for YOU


Do not give up on life!

Contact us 24/7 for free service matching:

Call center +44.2082.426.039

For further reading


To check if our service suits your case
We need to talk

Improve therapeutic outcomes, prolong life and quality of life, is our main business.
We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Popular topics